Tau PET correlates with different Alzheimer's disease‐related features compared to CSF and plasma p‐tau biomarkers

R Ossenkoppele, J Reimand, R Smith… - EMBO molecular …, 2021 - embopress.org
PET, CSF and plasma biomarkers of tau pathology may be differentially associated with
Alzheimer's disease (AD)‐related demographic, cognitive, genetic and neuroimaging …

[HTML][HTML] Gene-SGAN: discovering disease subtypes with imaging and genetic signatures via multi-view weakly-supervised deep clustering

Z Yang, J Wen, A Abdulkadir, Y Cui, G Erus… - Nature …, 2024 - nature.com
Disease heterogeneity has been a critical challenge for precision diagnosis and treatment,
especially in neurologic and neuropsychiatric diseases. Many diseases can display multiple …

Robustly uncovering the heterogeneity of neurodegenerative disease by using data-driven subtyping in neuroimaging: A review

P Chen, S Zhang, K Zhao, X Kang, T Rittman, Y Liu - Brain Research, 2023 - Elsevier
Neurodegenerative diseases are associated with heterogeneity in genetics, pathology, and
clinical manifestation. Understanding this heterogeneity is particularly relevant for clinical …

[HTML][HTML] Data-driven FDG-PET subtypes of Alzheimer's disease-related neurodegeneration

F Levin, D Ferreira, C Lange, M Dyrba… - Alzheimer's research & …, 2021 - Springer
Background Previous research has described distinct subtypes of Alzheimer's disease (AD)
based on the differences in regional patterns of brain atrophy on MRI. We conducted a data …

Cognitive domain harmonization and cocalibration in studies of older adults.

S Mukherjee, SE Choi, ML Lee, P Scollard… - …, 2023 - psycnet.apa.org
Objective: Studies use different instruments to measure cognitirating cognitive tests permit
direct comparisons of individuals across studies and pooling data for joint analyses. Method …

Personalized brain models identify neurotransmitter receptor changes in Alzheimer's disease

AF Khan, Q Adewale, TR Baumeister, F Carbonell… - Brain, 2022 - academic.oup.com
Alzheimer's disease involves many neurobiological alterations from molecular to
macroscopic spatial scales, but we currently lack integrative, mechanistic brain models …

Multi-scale semi-supervised clustering of brain images: Deriving disease subtypes

J Wen, E Varol, A Sotiras, Z Yang, GB Chand… - Medical image …, 2022 - Elsevier
Disease heterogeneity is a significant obstacle to understanding pathological processes and
delivering precision diagnostics and treatment. Clustering methods have gained popularity …

[HTML][HTML] Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease

MT Duong, SR Das, X Lyu, L Xie, H Richardson… - Nature …, 2022 - nature.com
Alzheimer's disease (AD) is defined by amyloid (A) and tau (T) pathologies, with T better
correlated to neurodegeneration (N). However, T and N have complex regional relationships …

[HTML][HTML] Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease

D Biel, Y Luan, M Brendel, P Hager, A Dewenter… - Alzheimer's Research & …, 2022 - Springer
Background Tau-PET is a prognostic marker for cognitive decline in Alzheimer's disease,
and the heterogeneity of tau-PET patterns matches cognitive symptom heterogeneity. Thus …

[HTML][HTML] Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia

G Salvadó, MJ Grothe, C Groot, A Moscoso… - European journal of …, 2021 - Springer
Purpose To examine associations between the APOE-ε2 and APOE-ε4 alleles and core
Alzheimer's disease (AD) pathological hallmarks as measured by amyloid-β (Aβ) and tau …